Arena Pharmaceuticals Inc. (ARNA)

40.55
0.60 1.50
NASDAQ : Health Technology
Prev Close 41.15
Open 41.13
Day Low/High 39.94 / 41.40
52 Wk Low/High 24.33 / 50.05
Volume 210.94K
Avg Volume 540.80K
Exchange NASDAQ
Shares Outstanding 49.35M
Market Cap 1.94B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Arena Pharmaceuticals Reports Positive Phase 2a Results For Olorinab In Patients With Abdominal Pain Associated With Crohn's Disease

Arena Pharmaceuticals Reports Positive Phase 2a Results For Olorinab In Patients With Abdominal Pain Associated With Crohn's Disease

- Olorinab demonstrated a statistically significant improvement in abdominal pain over 8 weeks of treatment

Arena Pharmaceuticals To Host R&D Day On October 4 In New York City

Arena Pharmaceuticals To Host R&D Day On October 4 In New York City

SAN DIEGO, Sept. 21, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals To Present At Upcoming Investor Conferences

Arena Pharmaceuticals To Present At Upcoming Investor Conferences

SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals Presents Preclinical Data For Olorinab At International Association For The Study Of Pain World Congress

Arena Pharmaceuticals Presents Preclinical Data For Olorinab At International Association For The Study Of Pain World Congress

SAN DIEGO, Sept. 17, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals To Present At Upcoming Investor Conferences

Arena Pharmaceuticals To Present At Upcoming Investor Conferences

SAN DIEGO, Aug. 29, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals Presented Phase 1 Clinical Data For Ralinepag In Pulmonary Arterial Hypertension At The European Society Of Cardiology

Arena Pharmaceuticals Presented Phase 1 Clinical Data For Ralinepag In Pulmonary Arterial Hypertension At The European Society Of Cardiology

SAN DIEGO, Aug. 28, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals Provides Corporate Update And Reports Second Quarter 2018 Financial Results

Arena Pharmaceuticals Provides Corporate Update And Reports Second Quarter 2018 Financial Results

- Initiated ADVANCE Phase 3 Program for Ralinepag in Pulmonary Arterial Hypertension (PAH)

Arena Pharmaceuticals To Release Second Quarter 2018 Financial Results And Provide Corporate Update On Monday, August 6

Arena Pharmaceuticals To Release Second Quarter 2018 Financial Results And Provide Corporate Update On Monday, August 6

SAN DIEGO, July 30, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its second quarter 2018 financial results and provide a corporate update on Monday, August 6, 2018, after the close of the U.

Arena Pharmaceuticals Appoints Life Sciences Industry Veteran Kieran T. Gallahue To Board Of Directors

Arena Pharmaceuticals Appoints Life Sciences Industry Veteran Kieran T. Gallahue To Board Of Directors

SAN DIEGO, July 10, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas, today announced the appointment of Kieran T.

First Week Of September 21st Options Trading For Arena Pharmaceuticals (ARNA)

First Week Of September 21st Options Trading For Arena Pharmaceuticals (ARNA)

Investors in Arena Pharmaceuticals Inc saw new options begin trading this week, for the September 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 86 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Sector Steps Up to Provide Some Strong Action for Traders

Biotech Sector Steps Up to Provide Some Strong Action for Traders

The S&P 500 has shown the same pattern for three consecutive days.

Will the Market Go Dead for a While?

Will the Market Go Dead for a While?

The best way to deal with it is to keep on hunting for individual stocks.

The Headlines Are Wrong -- This Is an Extremely Bullish Market

The Headlines Are Wrong -- This Is an Extremely Bullish Market

It is two totally different markets when you compare the small-cap action to the big-cap indices.

Small-Caps Are the Place to Be for Now

Small-Caps Are the Place to Be for Now

We are seeing a focus on finding smaller names that may offer interesting valuations and stories.

Market Bifurcation: Individual Stocks Are Acting Better Than the Indices

Market Bifurcation: Individual Stocks Are Acting Better Than the Indices

This underperformance is being caused by pockets of weakness in bigger-cap names.

Reminder: Healthy Stock Markets Decline, Too

Reminder: Healthy Stock Markets Decline, Too

The key for the overall market now is that it hold above today's early lows.

Many Names on My Radar

Many Names on My Radar

There is no question that we are becoming extended and ripe for some profit taking.

Trump's Drug Pricing Plan Makes Me Want to Play Ball With Biotech Stocks

Trump's Drug Pricing Plan Makes Me Want to Play Ball With Biotech Stocks

Sector charts should shape up as worries about prices are finally put to rest.

Having Some Good Luck With Biotech Names

Having Some Good Luck With Biotech Names

Overall it is still a positive day but the action is sloppy.

Markets Make an Art of Unpredictability

Markets Make an Art of Unpredictability

Oil isn't the only reason stocks are higher.

Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern

Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern

Finding good setups in individual stocks is still challenging as there simply isn't a lot of strong momentum.

Smaller Companies Are Often Some of the Best Trading Vehicles

Smaller Companies Are Often Some of the Best Trading Vehicles

The challenge of this market is that the upward moves have not been well sustained.

Arena Pharmaceuticals And Outpost Medicine Enter Into Licensing Agreement For Undisclosed Novel Compound

- Arena's non-core, proprietary, preclinical compound provides strategic fit with Outpost Medicine's expertise in developing products for genitourinary disorders

Walgreens, Arena Pharma, Dominion Energy: 'Mad Money' Lightning Round

Walgreens, Arena Pharma, Dominion Energy: 'Mad Money' Lightning Round

Jim Cramer focuses on Walgreens Boots Alliance, Arena Pharmaceutical, Dominion Energy, Tower Semiconductor, Idexx, LexinFintech Holdings and more.

FANG, Tariffs, Trade: Cramer's 'Mad Money' Recap (Thursday 4/26/18)

FANG, Tariffs, Trade: Cramer's 'Mad Money' Recap (Thursday 4/26/18)

It's not all about the bond market, says Jim Cramer. The central issues here are trade, tariffs and most important, the stocks themselves, like Facebook and Amazon.

TheStreet Quant Rating: D (Sell)